Enovis CORP Q1 FY2025 earnings call

Management Statement and Operational Highlights:

• Had a strong start to 2025 with 8% reporting growth and 11% comparable growth, aligning with high single-digit strategic goals.
• Expanded adjusted EBITDA margins by 160 basis points due to Recon mix, stable pricing, and EGX-driven productivity improvements.
• Recent and upcoming new product launches in Recon (augmented reverse glenoid system in shoulders, nebula stem and surgical impactor in hip, next generation of ARVIS hardware and software) and P&R (Manafuse LIPUS technology launch in recovery sciences and key new bracing products) were highlighted.

Segment Performance:

• Recon: Delivered comparable growth of 13%. U.S. Recon grew 11% (12% in U.S. extremities, 10% in hips and knees), and international Recon grew 14% in a resilient market.
• P&R: Achieved 8% comparable growth, reflecting a stable market environment, disciplined execution, and additional selling days.

Guidance:

• Reiterated 2025 organic constant currency revenue growth of 6% to 6.5% year-over-year, increasing revenue range to $2.22 billion to $2.25 billion due to favorable currency impact.
• Lowered adjusted EBITDA range to $385 million to $395 million due to incremental tariffs in the second half of 2025.
• Updated adjusted EPS range to $2.95 to $3.10, down $0.15 from prior guidance.
• Maintained expectation for positive free cash flow in 2025.

Risks:

• Tariff exposure, with approximately $40 million of 2025 tariff exposure, primarily from China. Plans to mitigate by shifting sourcing to other geographies, but the tariff situation remains fluid.

Question and Answer: Q: Vik Chopra asks about the most significant potential to create durable supply availability over the long-term.

A: Matt Trerotola states quickly moving sourcing of products out of China is the best opportunity, as most tariff exposure is from China and they've been working on shifting sourcing.

Q: Vik Chopra follows up on ARG launch and U.S. market trends.

A: Matt Trerotola says ARG launch is going terrifically, and the U.S. market had a healthy start with strong January and February, though March had some slowdown.

Q: Vijay Kumar asks about U.S. performance in bracing and Recon.

A: Matt Trerotola mentions strong start in bracing, consistent with market environment, and Recon Q1 was in line with expectations with quarter-by-quarter progression.

Q: Vijay Kumar asks about gross margin sustainability.

A: Ben Berry says it's due to positive business mix, new products, and continued shaping towards higher gross margin performance.

Q: Robert Marcus asks about second quarter guidance and cash flow.

A: Ben Berry states second quarter is in line with prior outlook, and first quarter cash flow is seasonally low but expects improvement through the year.

Q: Unidentified Analyst asks about ARVIS shoulder launch progress.

A: Matt Trerotola says ARVIS shoulder launch is going well with positive surgeon response and buzz around the shoulder business.

Q: Unidentified Analyst asks about new product launch cadence.

A: Matt Trerotola outlines strong lineup of new product launches across Recon and P&R, with various products ramping.

Q: Dane Reinhardt asks about CapEx and extremities subsegments.

A: Ben Berry talks about elevated CapEx for operational synergies and growth, and Matt Trerotola says shoulder drove extremities growth in Q1 with foot and ankle still above market.

Q: Danielle Antalffy asks about business recession-proofing and margin goals.

A: Matt Trerotola says business markets are generally recession-resistant, and Ben Berry states they're still bullish on profitable growth despite 2025 tariff implications.

Q: Unidentified Analyst asks about EBITDA margin vs gross margin.

A: Ben Berry says it's due to investments in growth, operating expense phasing, and medical education.

Q: Unidentified Analyst asks about Manafuse launch.

A: Matt Trerotola says Manafuse expands the market, drives growth, and there's no meaningful reclassification risk.

Q: Russell Yuen asks about pricing environment and Recon international cross-selling.

A: Matt Trerotola talks about Recon price environment trend and international team's strong growth with durable cross-selling potential.

Q: Young Li asks about tariff mitigation and SKU optimization.

A: Ben Berry says they're aggressively working on shifting sourcing and SKU optimization, with conservative guidance contemplating some moves.